Truemeds Is Buying DealShare For Roughly What Sits In Its Bank Account

In this storyDealShareTruemeds

Truemeds is in advanced talks to acquire DealShare in a share-swap transaction that would value the e-commerce company at a little over $90 million, the Economic Times reported. Entrackr first reported last week that DealShare was seeking a buyer.

The figure is roughly 95 per cent below the $1.7 billion DealShare commanded in 2022. It is also only marginally above the company's cash balance, which stands at more than $90 million. Under the proposed structure, Truemeds would issue its own shares to DealShare's investors at an implied valuation of around $600 million, letting it absorb DealShare's cash without paying anything out of its own treasury. Terms are still being finalised, and neither company responded to Inc42's queries.

DealShare was founded in 2018 by Sourjyendu Medda, Vineet Rao, Sankar Bora and Rajat Shikhar as a community-led platform selling groceries and household essentials to price-conscious shoppers in smaller cities. It raised about $393 million from Tiger Global, Alpha Wave Global, the Abu Dhabi Investment Authority, Kora Investment, WestBridge Capital and Z47. It crossed a billion dollars in January 2022 on a $165 million Series E, and a subsequent $45 million cheque from ADIA set the $1.7 billion mark.

The descent since has been steep. Gross revenue from operations fell from ₹1,963 crore in FY23 to ₹499 crore in FY24 and ₹432 crore in FY25. Losses narrowed across the same stretch, from ₹502 crore to ₹167 crore to ₹87.65 crore. FY26 accounts have not been filed. The company shut its B2B vertical and cut more than 100 jobs during FY24.

Captain Fresh was also in discussions. Entrackr's sources said DealShare would likely wind down if no deal closes.

Strip away the headline percentage and the structure says everything. A buyer paying a little over $90 million for a company holding more than $90 million in cash is paying close to nothing for the business itself. This is not a discounted acquisition. It is a wind-down with a better ending, in which the cash finds a new owner and the operating entity comes along at no charge.

The currency is the other half of it. Truemeds is not writing a cheque. It is issuing paper marked at roughly $600 million. Its last widely reported priced round, led by Accel with Peak XV, put it somewhere between $330 million and $410 million. Whether $600 million reflects eighteen months of genuine growth or is a convenient number for this particular transaction is the question DealShare's investors have to settle, because they are the ones being asked to accept it.

What they give up is certainty. Cash on a balance sheet is worth exactly what it says. Shares in a private company are worth whatever the next round decides. Tiger Global, Alpha Wave, ADIA and Kora put a little over $200 million into DealShare at or near its peak, and they are being offered the chance to convert a known, small recovery into an unknown, larger one.

WestBridge Capital sits on both sides of this table. That is common in transactions of this kind, and it is worth stating plainly.

The instructive part of DealShare's story is not the valuation. It is that the turnaround worked and the company died anyway.

Look at the three years again. Revenue fell from ₹1,963 crore to ₹432 crore. Losses fell from ₹502 crore to ₹88 crore. By the standard metrics of the 2023-24 correction, that reads as a success. The company cut costs, closed a loss-making B2B arm, shed headcount and moved decisively towards breakeven. It did what the market asked. What emerged at the end was a business too small to sustain itself, with every founder gone and a balance sheet whose most valuable line item was the money it had not yet spent.

That is the lesson for the rest of the 2021-22 cohort still working through this. Efficiency is not a strategy. Cutting your way to profitability only works if there is a defensible business at the bottom of the cut. Thin-margin grocery, fulfilled into small cities, against horizontal marketplaces and quick commerce, was not that.

It also lands on the same day as GlobalData figures showing India taking 1 per cent of global venture funding value. This is what that statistic looks like at company level. Z47 has already written off its DealShare position. The others are being offered five cents on the dollar, payable in someone else's stock. When Indian exits price like this, the next Indian round prices accordingly, and the reluctance eventually shows up as a share of global capital.

Two things worth holding open. A share swap that keeps a business breathing and hands investors equity in a growing company beats liquidation, which was the alternative on the table. And Truemeds is a real business, with 2025 revenue reported at about $58 million, buying distribution reach in precisely the markets DealShare was built to serve. If that network still functions, this is a sensible trade rather than a salvage operation. How much of it still functions is the question nobody has answered.

For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.